{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T12:38:49Z","timestamp":1722861529364},"reference-count":37,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2013,8,1]],"date-time":"2013-08-01T00:00:00Z","timestamp":1375315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medical Hypotheses"],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1016\/j.mehy.2013.04.042","type":"journal-article","created":{"date-parts":[[2013,5,18]],"date-time":"2013-05-18T09:03:36Z","timestamp":1368867816000},"page":"231-234","source":"Crossref","is-referenced-by-count":7,"title":["Does spironolactone ameliorate trastuzumab-induced cardiac toxicity?"],"prefix":"10.1016","volume":"81","author":[{"given":"Guler","family":"Yavas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rengin","family":"Elsurer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cagdas","family":"Yavas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cagdas","family":"Elsurer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ozlem","family":"Ata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.mehy.2013.04.042_b0005","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1038\/sj.onc.1201331","article-title":"HER2\/neu and the Ets transcription activator PEA3 are coordinately upregulated in human breast cancer","volume":"15","author":"Benz","year":"1997","journal-title":"Oncogene"},{"key":"10.1016\/j.mehy.2013.04.042_b0010","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1177\/1534735408330717","article-title":"Trastuzumab and doxorubicin related cardiotoxicity and the cardioprotective role of exercise","volume":"8","author":"Wonders","year":"2009","journal-title":"Integr Cancer Ther"},{"key":"10.1016\/j.mehy.2013.04.042_b0015","first-page":"1027","article-title":"Node negative breast cancers with p53 (-)\/HER2-neu status may identify women with very good prognosis","volume":"16","author":"Albanell","year":"1996","journal-title":"Anticancer Res"},{"key":"10.1016\/j.mehy.2013.04.042_b0020","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa052122","article-title":"Trastuzumab plus adjuvant chemotherapy for operable HER-2 positive breast cancer","volume":"353","author":"Romond","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.mehy.2013.04.042_b0025","unstructured":"Perez E.A., Suman V.J., Davidson N. et al. NCCTG N9831, May 2005 update Presented at the 45th annual meeting of the American Society of Clinical Oncology Orlando FL, May 16, 2005."},{"key":"10.1016\/j.mehy.2013.04.042_b0030","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(07)60028-2","article-title":"2-Year follow-up of trastuzumab after adjuvant chemotherapy in HER-2 positive breast cancer: a randomized controlled trial","volume":"369","author":"Smith","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.mehy.2013.04.042_b0035","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa053028","article-title":"Adjuvant docetaxel or vineralbine with or without trastuzumab for breast cancer","volume":"354","author":"Joensuu","year":"2006","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.mehy.2013.04.042_b0040","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1200\/JCO.2008.17.9549","article-title":"Radiotherapy and adjuvant trastuzumab in operable breast cancer: tolerability and adverse event data from the NCCTG phase III trial N9831","volume":"27","author":"Halyard","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.mehy.2013.04.042_b0045","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1200\/JCO.20.3.719","article-title":"Adjuvant docetaxel or vineralbine with or without trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer","volume":"20","author":"Vogel","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.mehy.2013.04.042_b0050","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus monoclonal antibody against HER 2 for metastatic breast cancer that overexpresses HER 2","volume":"344","author":"Slamon","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.mehy.2013.04.042_b0055","doi-asserted-by":"crossref","first-page":"3965","DOI":"10.1200\/JCO.2003.12.109","article-title":"Pharmacokinetics, safety and efficacy of trastuzumab administered every three weeks in combination with paclitaxel","volume":"21","author":"Leyland Jones","year":"2003","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.mehy.2013.04.042_b0060","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1200\/JCO.20.5.1215","article-title":"Cardiac dysfunction in the Trastuzumab clinical trials experience","volume":"20","author":"Seiman","year":"2002","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.mehy.2013.04.042_b0065","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0025-6196(11)60840-9","article-title":"Trastuzumab-induced cardiotoxicity: heart failure at the crossroads","volume":"83","author":"Sengupta","year":"2008","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.mehy.2013.04.042_b0070","first-page":"20","article-title":"Myocyte survival pathways and cardiomyopathy: implications for Trastuzumab cardiotoxicity","volume":"28","author":"Chen","year":"2000","journal-title":"Semin Oncol"},{"key":"10.1016\/j.mehy.2013.04.042_b0075","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/nrc2106","article-title":"Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition","volume":"7","author":"Force","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.mehy.2013.04.042_b0080","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1056\/NEJMra043186","article-title":"Trastuzumab-mechanism of action and use in clinical practice","volume":"357","author":"Hudis","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.mehy.2013.04.042_b0085","doi-asserted-by":"crossref","first-page":"R944","DOI":"10.1152\/ajpregu.2001.281.3.R944","article-title":"Spironolactone reduces cerebral infarct size and EGF-receptor mRNA in stroke-prone rats","volume":"281","author":"Dorrance","year":"2001","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"10.1016\/j.mehy.2013.04.042_b0090","doi-asserted-by":"crossref","first-page":"R878","DOI":"10.1152\/ajpregu.2001.281.3.R878","article-title":"Mineralocorticoids upregulate arterial contraction to epidermal growth factor","volume":"281","author":"Florian","year":"2001","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"10.1016\/j.mehy.2013.04.042_b0095","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1291\/hypres.28.925","volume":"28","author":"Nakano","year":"2005","journal-title":"Hypertens Res"},{"key":"10.1016\/j.mehy.2013.04.042_b0100","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1161\/CIRCULATIONAHA.104.521625","article-title":"Aldosterone synthase inhibitor ameliorates angiotensin II-induced organ damage","volume":"111","author":"Fiebeler","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.mehy.2013.04.042_b0105","doi-asserted-by":"crossref","first-page":"43060","DOI":"10.1074\/jbc.M308134200","article-title":"Aldosterone stimulates epidermal growth factor receptor (EGFR) expresssion","volume":"278","author":"Krug","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.mehy.2013.04.042_b0110","first-page":"378","article-title":"Requirement for neureguli receptor erbB2 in neural and cardiac development","author":"Lee","year":"1995","journal-title":"Nature"},{"key":"10.1016\/j.mehy.2013.04.042_b0115","doi-asserted-by":"crossref","first-page":"4999","DOI":"10.1242\/dev.124.24.4999","article-title":"ErbB3 is required for normal cerebellar and cardiac development: a comparison with ErbB2-and heregulin-deficient mice","volume":"124","author":"Erickson","year":"1997","journal-title":"Development"},{"key":"10.1016\/j.mehy.2013.04.042_b0120","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/nm0502-459","article-title":"ErbB2 is essential in the perevention of dilated cardiomyopathy","volume":"8","author":"Crone","year":"2002","journal-title":"Nat Med"},{"key":"10.1016\/j.mehy.2013.04.042_b0125","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ejheart.2006.05.010","article-title":"Serum HER2 levels are increased in patients with chronic heart failure","volume":"9","author":"Perik","year":"2007","journal-title":"Eur J Heart Fail"},{"issue":"31","key":"10.1016\/j.mehy.2013.04.042_b0130","doi-asserted-by":"crossref","first-page":"7820","DOI":"10.1200\/JCO.2005.13.300","article-title":"Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment","volume":"23","author":"Ewer","year":"2005","journal-title":"J Cin Oncol"},{"issue":"25","key":"10.1016\/j.mehy.2013.04.042_b0135","doi-asserted-by":"crossref","first-page":"4107","DOI":"10.1200\/JCO.2005.04.9551","article-title":"Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the MD Anderson cancer center experience","volume":"24","author":"Guarneri","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.mehy.2013.04.042_b0140","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.steroids.2007.12.008","article-title":"Nongenotropic aldosterone effects and the EGFR: interaction and biological relevance","volume":"73","author":"Grossmann","year":"2008","journal-title":"Streoids"},{"key":"10.1016\/j.mehy.2013.04.042_b0145","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/nm0102-35","article-title":"Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: metalloproteinase inhibitors as a new therapy","volume":"8","author":"Asakura","year":"2002","journal-title":"Nat Med"},{"key":"10.1016\/j.mehy.2013.04.042_b0150","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1038\/47260","article-title":"EGF-receptor transactivation by G-protein-coupled receptors requires metalloprotesae cleavage of proHB-EGF","volume":"402","author":"Prensel","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.mehy.2013.04.042_b0155","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1161\/01.RES.0000147962.01036.bb","article-title":"Transactivation of epidermal growth factor receptor mediates catecholamine-induced growth of vascular smooth muscle","volume":"95","author":"Zhand","year":"2004","journal-title":"Circ Res"},{"key":"10.1016\/j.mehy.2013.04.042_b0160","doi-asserted-by":"crossref","first-page":"C446","DOI":"10.1152\/ajpcell.00261.2001","article-title":"EGF receptor transactivation is obligatory for protein synthesis stimulation by G protein-coupled receptors","volume":"283","author":"Voisin","year":"2002","journal-title":"AJP-Cell Physiol"},{"key":"10.1016\/j.mehy.2013.04.042_b0165","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1073\/pnas.97.2.931","article-title":"Overexpression of angiotensin II type I receptor in cardiomyocytes induced cardiac hypertrophy and remodeling","volume":"97","author":"Paradis","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"10.1016\/j.mehy.2013.04.042_b0175","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1053\/j.seminoncol.2005.11.001","article-title":"Anticancer agents and cardiotoxicity","volume":"33","author":"Ng","year":"2006","journal-title":"Semin Oncol"},{"issue":"23","key":"10.1016\/j.mehy.2013.04.042_b0180","doi-asserted-by":"crossref","first-page":"3525","DOI":"10.1200\/JCO.2007.11.0106","article-title":"Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility","volume":"25","author":"Telli","year":"2007","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.mehy.2013.04.042_b0185","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1161\/01.CIR.102.3.272","article-title":"Trastuzumab in the treatment of metastatic breast cancer: anticancer therapy versus cardiotoxicity","volume":"102","author":"Feldman","year":"2000","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.mehy.2013.04.042_b0190","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/nrd2332","article-title":"Lapatinib","volume":"6","author":"Moy","year":"2007","journal-title":"Nat Rev Drug Discov"}],"container-title":["Medical Hypotheses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987713002235?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987713002235?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,2,17]],"date-time":"2022-02-17T11:05:53Z","timestamp":1645095953000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0306987713002235"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,8]]}},"alternative-id":["S0306987713002235"],"URL":"https:\/\/doi.org\/10.1016\/j.mehy.2013.04.042","relation":{},"ISSN":["0306-9877"],"issn-type":[{"value":"0306-9877","type":"print"}],"subject":[],"published":{"date-parts":[[2013,8]]}}}